Q-omics provides the consensus-scored RP9P profile across patient tissues and cancer cell-line models. RP9P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RP9P is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, RP9P RNA expression shows 18,603 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where RP9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RP9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RP9P survival associations across molecular data types. RP9P RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RP9P RNA expression–survival associations across cancer types. High RP9P expression shows unfavorable associations in LIHC, KIRC, ACC, LGG and BLCA, but favorable associations in THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RP9P RNA expression.
This table summarizes RP9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RP9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RP9P shows higher tumor expression in KIRC, COAD, LIHC, KIRP, HNSC and THCA. The KIRC box plot shows higher RP9P RNA expression in tumor versus normal tissue (log2 FC = +0.816, t-test p < 0.001).
This table shows molecular features associated with RP9P in patient tissues and cancer cell lines. In patient samples, RP9P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
